

IN THE CLAIMS

1-32 (canceled)

33. (previously presented) A replication-competent adenovirus vector comprising a first and a second adenovirus gene essential for replication, wherein said first adenovirus gene is under transcriptional control of a carcinoembryonic antigen transcription regulatory element (CEA-TRE) and said second adenovirus gene is under transcriptional control of a cell-specific, tissue-specific or cancer-specific heterologous transcriptional ~~response~~ regulatory element (TRE).

34-35. (canceled)

36. (currently amended) The adenovirus vector of claim 33 wherein said CEA-TRE comprises a promoter that comprises a ~~nucleotide~~ polynucleotide sequence within about -402 to about +69 nucleotides relative to the transcriptional start site of the CEA gene and a CEA enhancer.

37. (canceled)

38. (previously presented) A composition comprising the adenovirus vector of claim 33, and a pharmaceutically acceptable excipient.

39. (previously presented) A host cell transformed with the adenovirus vector of claim 33.

40. (previously presented) The adenovirus vector of Claim 33, wherein said adenovirus gene essential for replication is an early gene.

41. (previously presented) The adenovirus vector of Claim 40, wherein said early gene is selected from the group consisting of E1A, E1B and E4.

42. (previously presented) The adenovirus vector of Claim 33, wherein said first and said second adenovirus gene essential for replication are E1A and E1B.

43. (currently amended) The adenovirus vector of Claim 36 wherein said CEA enhancer comprises a ~~nucleotide~~ polynucleotide sequence from about -6.1 to about -3.8 kilobases relative to

the transcriptional start site of the CEA gene.

44. (currently amended) The adenovirus vector of Claim 36 wherein said CEA enhancer comprises a ~~nucleotide~~ polynucleotide sequence from about -14.5 to about -3.8 kilobases relative to the transcriptional start site of the CEA gene.

45. (previously presented) The adenovirus vector of Claim 36 wherein said CEA promoter comprises the nucleotide sequence as shown in SEQ ID NO:1.

46. (currently amended) The adenovirus vector of Claim 36 wherein said CEA enhancer comprises a ~~nucleotide~~ polynucleotide sequence within the region from about -13.6 to about -10.6 kilobases relative to the transcriptional start site of the CEA gene.

47. (currently amended) The adenovirus vector of Claim 36 wherein said CEA enhancer comprises ~~the nucleotide~~ a polynucleotide sequence from about -14.5 to about -10.6 kilobases relative to the transcriptional start site of the CEA gene.

48. (previously presented) The adenovirus vector of Claim 36 wherein said CEA promoter is a sequence having at least 85% sequence identity to nucleotides -402 to +69 as depicted in SEQ ID NO:1, wherein said promoter component retains the ability to increase transcription of an operably linked polynucleotide.

49. (previously presented) The adenovirus vector of Claim 36 wherein said CEA promoter is a sequence having at least 90% sequence identity to nucleotides -402 to +69 as depicted in SEQ ID NO:1, wherein said promoter component retains the ability to increase transcription of an operably linked polynucleotide.

50. (previously presented) The adenovirus vector of Claim 36 wherein said CEA promoter is a sequence having at least 95% sequence identity to nucleotides -402 to +69 as depicted in SEQ ID NO:1, wherein said promoter component retains the ability to increase transcription of an operably linked polynucleotide.